These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24439863)

  • 1. Effects of eplerenone on P-wave signal-averaged electrocardiogram in hypertensive patients with coronary artery disease.
    Kurisu S; Watanabe N; Ikenaga H; Shimonaga T; Higaki T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Kihara Y
    Int J Cardiol; 2014; 172(1):e180-1. PubMed ID: 24439863
    [No Abstract]   [Full Text] [Related]  

  • 2. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone might affect atrial fibrosis in patients with hypertension.
    Kawasaki M; Yamada T; Okuyama Y; Morita T; Furukawa Y; Tamaki S; Iwasaki Y; Kikuchi A; Sakata Y; Fukunami M
    Pacing Clin Electrophysiol; 2017 Oct; 40(10):1096-1102. PubMed ID: 28845908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacology profile and clinical findings of Selara Tablets (eplerenone)].
    Nomura S; Tabira J; Hayashi T; Hamada Y
    Nihon Yakurigaku Zasshi; 2008 Oct; 132(4):227-35. PubMed ID: 18854625
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
    Colussi G; Catena C; Sechi LA
    J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone. Pharmacia.
    Liew D; Martin J; Krum H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Eplerenone in resistant hypertension with previous spironolactone intolerance].
    Antonio Costa J; Rodilla E; Pérez-Lahiguera F; María Pascual J
    Med Clin (Barc); 2009 May; 132(19):756-7. PubMed ID: 19243793
    [No Abstract]   [Full Text] [Related]  

  • 9. Eplerenone's role in the management of complex cardiovascular disorders.
    Stewart Coats AJ; Shewan L
    Int J Cardiol; 2015 Dec; 200():1-2. PubMed ID: 26116081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats.
    Burla AK; Neves MF; Oigman W; Mandarim-de-Lacerda CA
    Int J Cardiol; 2007 Jan; 114(1):64-70. PubMed ID: 16650491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological sheet: eplerenone (Inspra), orally].
    J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
    Takeda Y
    Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
    Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
    Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving strategies for the use of spironolactone in cardiovascular disease.
    Jolobe OM
    Eur J Intern Med; 2013 Jun; 24(4):303-9. PubMed ID: 23245930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does eplerenone have a future in the management of hypertension in Europe?
    Gosse P; Macfadyen RJ
    J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301
    [No Abstract]   [Full Text] [Related]  

  • 20. Eplerenone (GD Searle & Co).
    Martin J; Krum H
    Curr Opin Investig Drugs; 2001 Apr; 2(4):521-4. PubMed ID: 11566010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.